Vincerx Pharma (NASDAQ:VINC) Stock Rating Reaffirmed by Cantor Fitzgerald

Vincerx Pharma (NASDAQ:VINCGet Rating)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Vincerx Pharma’s FY2022 earnings at ($2.76) EPS and FY2023 earnings at ($2.00) EPS.

VINC has been the topic of several other research reports. SVB Leerink dropped their price objective on Vincerx Pharma from $6.00 to $5.00 and set an “outperform” rating on the stock in a research note on Friday, August 12th. Chardan Capital dropped their price objective on Vincerx Pharma from $11.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, June 7th. Finally, B. Riley dropped their price objective on Vincerx Pharma from $12.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, June 7th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $10.20.

Vincerx Pharma Stock Down 10.0 %

Shares of NASDAQ VINC opened at $1.08 on Wednesday. Vincerx Pharma has a twelve month low of $1.03 and a twelve month high of $17.49. The stock’s 50 day moving average price is $1.47 and its 200-day moving average price is $2.18. The company has a market capitalization of $22.89 million, a PE ratio of -0.32 and a beta of 1.28.

Vincerx Pharma (NASDAQ:VINCGet Rating) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.04. As a group, research analysts expect that Vincerx Pharma will post -2.65 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Christopher P. Lowe purchased 18,400 shares of the firm’s stock in a transaction dated Wednesday, August 24th. The shares were purchased at an average price of $1.65 per share, with a total value of $30,360.00. Following the completion of the acquisition, the director now owns 28,400 shares in the company, valued at approximately $46,860. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. In other news, insider Raquel E. Izumi purchased 40,000 shares of the firm’s stock in a transaction dated Monday, June 27th. The shares were purchased at an average price of $1.41 per share, with a total value of $56,400.00. Following the completion of the acquisition, the insider now owns 40,000 shares in the company, valued at approximately $56,400. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Christopher P. Lowe purchased 18,400 shares of the firm’s stock in a transaction dated Wednesday, August 24th. The stock was purchased at an average cost of $1.65 per share, for a total transaction of $30,360.00. Following the acquisition, the director now owns 28,400 shares of the company’s stock, valued at approximately $46,860. The disclosure for this purchase can be found here. Company insiders own 23.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Rock Springs Capital Management LP grew its stake in shares of Vincerx Pharma by 0.6% during the first quarter. Rock Springs Capital Management LP now owns 814,194 shares of the company’s stock valued at $3,257,000 after buying an additional 4,999 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Vincerx Pharma by 21.3% during the second quarter. Goldman Sachs Group Inc. now owns 36,126 shares of the company’s stock valued at $48,000 after buying an additional 6,334 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Vincerx Pharma by 1.8% during the first quarter. Vanguard Group Inc. now owns 666,019 shares of the company’s stock valued at $2,664,000 after buying an additional 11,667 shares during the last quarter. Rhumbline Advisers bought a new position in shares of Vincerx Pharma during the first quarter valued at about $53,000. Finally, Schonfeld Strategic Advisors LLC grew its stake in shares of Vincerx Pharma by 8.0% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 292,477 shares of the company’s stock valued at $2,980,000 after buying an additional 21,655 shares during the last quarter. Institutional investors own 65.91% of the company’s stock.

Vincerx Pharma Company Profile

(Get Rating)

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies.

Featured Stories

Analyst Recommendations for Vincerx Pharma (NASDAQ:VINC)

Receive News & Ratings for Vincerx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vincerx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.